News Drug Development

Dendreon Corporation Sees Positive Results From Provenge

November 10, 2006 |

1 min read

NEW YORK, Nov 10 (Reuters) - Dendreon Corp. (DNDN.O: Quote, Profile, Research) said on Friday analysis of its Provenge immunotherapy for the treatment of advanced prostate cancer showed positive results.

>>> Discuss This Story

Clinical research Postmarket research

MORE ON THIS TOPIC

Model of the lungs with the diseased part. Cancer or Ground glass opacity GGO.

Lung cancer

Summit, BioNTech, more headline WCLC with next-gen lung cancer drugs

September 14, 2026

·

4 min read

·

Gabrielle Masson

This 3D rendering encapsulates the concept of a winning strategy in business, emphasizing productivity, innovation, and the importance of female leadership. The imagery represents the synergy of teamwork, where diverse ideas and collaborative efforts drive success and growth. It highlights the critical role of women in leadership positions, showcasing their contributions to strategic planning and innovation. This visual serves as an inspiring representation of how inclusive leadership and innovative thinking can propel a business toward achieving its goals and maintaining a competitive edge in the market.

Psychedelics

Definium moves toward FDA submission for LSD drug in anxiety after ‘another clear win’

September 14, 2026

·

3 min read

·

Heather McKenzie

vector illustration arrows miss the target board, concept of lost in focus, failure, fail, mistake

Breast cancer

AstraZeneca’s newly approved cancer pill fails late-stage study, blocking path to bigger market

September 14, 2026

·

2 min read

·

Tristan Manalac

Glucagon-like peptide 1 (GLP1, 7-36) molecule The glucagon like peptide-1 receptor has a strong effect on the management of type 2 diabetes mellitus. 3d rendering

IN PARTNERSHIP WITH VIVA BIOTECH

Cyclic peptides open new drug frontiers, if manufacturing can keep up

September 14, 2026

·

6 min read

·

Jennifer C. Smith-Parker